In an announcement, the off-the-shelf vaccine ELI-002 7P elicited strong mKRAS-specific T-cell responses in 89 out of 90, or approximately 99%, of evaluable patients with pancreatic cancer. The data were announced in a news release issued by Elicio Therapeutics, a clinical-stage biotechnology company that developed the cancer vaccine. “We are extremely encouraged by the T-cell immunogenicity data from the ongoing phase 2 ELI-002 7P trial,” commented Robert Connelly, Chief Executive Officer of Elicio, in the news release. The ELI-002 7P iteration of the vaccine is intended to provide an immune response against seven of the most common KRAS mutations found in a quarter of all solid tumors. “It's the highest risk of recurrence after a cancer has been removed compared to any others—breast, colon, lung, you name it.